tradmap

CRDF Cardiff Oncology, Inc.

$1.21 +2.54%

Healthcare · Biological Products, (No Diagnostic Substances)

Cardiff Oncology, Inc. (CRDF) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $83 million. Shares last traded at $1.21, 74.5% below their 52-week high. Over the past year the stock is down 62.2%. Net profit margin is -7.7%, below the peer median of 6.3%. Revenue declined 13.2% year over year.

Market Cap
$83M
Shares Out
68.4M
EPS (TTM)
$-1.37
P/E Ratio
P/S Ratio
139.51
P/B Ratio
2.38
Dividend / Share
Dividend Yield
52-Week High
$4.74
52-Week Low
$1.16
Volume
74,380
Avg Vol (3m)
58,066.079

Performance

1W
-24.61%
1M
-30.86%
3M
-33.52%
6M
-49.69%
YTD
-54.68%
1Y
-62.19%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
35.22
SMA (50)
$1.64
SMA (200)
$2.03
Price vs SMA50
-26.06%
Price vs SMA200
-40.28%
ATR (14)
$0.14

Financials

Revenue
$1M
Net Income
$-0M
Gross Margin
Operating Margin
-8256.3%
Net Margin
-7.7%
Return on Equity
-0.1%
Return on Assets
-0.1%
Current Ratio
3.27
Debt / Equity
0.42
Revenue Growth (YoY)
-13.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.18 2026-05-14
FY 2025 $-0.69 2026-02-24
Q3 2025 $-0.58 2025-11-06
Q2 2025 $-0.41 2025-07-29
Q1 2026 $-0.20 2026-05-14
FY 2025 $-0.95 2026-02-24

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CRDF vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
139.51 / 5.21 med
+2576% premium
Net margin vs peers
-7.7% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.